Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. From throat lozenge manufacturers, pharmaceutical companies, and contract manufacturing organizations (CMOs), supply-side sources included CEOs, VPs of Product Development, regulatory affairs chiefs, R&D directors, and commercial directors. Retail pharmacists, pharmacy buyers, category managers from drugstore chains, supermarket health product buyers, e-commerce platform managers, and procurement leads from hospital pharmacies and clinic dispensaries constituted demand-side sources. Primary research verified market segmentation based on type (hard candy, soft, compressed), ingredient (menthol, mint, eucalyptus, honey & ginger, lemon), and indication (sore throat, cough and cold, throat diseases), and confirmed product pipeline timelines. Additionally, it gathered insights on seasonal demand patterns, pricing strategies, distribution channel dynamics, and private label growth trends.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (38%), Europe (29%), Asia-Pacific (26%), Rest of World (7%)
Global market valuation was derived through revenue mapping and consumption volume analysis. The methodology included:
Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across hard candy lozenges, soft lozenges, compressed lozenges, and ingredient categories (menthol, mint, eucalyptus oil, peppermint oil, honey & ginger, lemon, and others)
Analysis of reported and modeled annual revenues specific to throat lozenge portfolios
Coverage of manufacturers representing 72-78% of global market share in 2024
Extrapolation using bottom-up (consumption volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations